Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study

References

• World Health Organization. Immunization, Vaccines and Biologicals. Typhoid. Accessed on June 04, 2015 Available at http://wwwwhoint/immunization/diseases/typhoid/en/
   Google Scholar
• Kanungo S, Dutta S, Sur D. Epidemiology of typhoid and paratyphoid fever in India. J Infect Dev Ctries 2008; 2:454-60; PMID:19745523
   PubMed Web of Science ®Google Scholar
• Banerjee T, Shukla BN, Filgona J, Anupurba S, Sen MR. Trends of typhoid fever seropositivity over ten years in north India. Indian J Med Res 2014; 140:310-3; PMID:25297367
   PubMed Web of Science ®Google Scholar
• Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999; 67:5806-10; PMID:10531232
   PubMed Web of Science ®Google Scholar
• Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis 1989; 11 Suppl 3:S552-67; PMID:2669099; http://dx.doi.org/10.1093/clinids/11.Supplement_3.S552
   PubMedGoogle Scholar
• Engels EA, Lau J. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2000; 2000(2):CD001261; PMID:10796623
   PubMedGoogle Scholar
• Fraser A, Goldberg E, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2007; 2000(2):CD001261; PMID:17636661
   PubMedGoogle Scholar
• Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2014; 1:CD001261; PMID:24385413
   PubMed Web of Science ®Google Scholar
• Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine 1998; 16:1391-5; PMID:9711777; http://dx.doi.org/10.1016/S0264-410X(98)00097-8
   PubMed Web of Science ®Google Scholar
• Chinnasami B, Mangayarkarasi V, Prema A, Sadasivam K, Davis MJ. Safety and Immunogenicity of Salmonella Typhi Vi conjugate vaccine (PedaTyph™) in children upto five years. Int J Scientific Res Pub 2013; 3:1-5
   Google Scholar
• Ochiai RL, Khan MI, Soofi SB, Sur D, Kanungo S, You YA, Habib MA, Sahito SM, Manna B, Dutta S, et al. Immune responses to Vi capsular polysaccharide typhoid vaccine in children 2 to 16 years old in Karachi, Pakistan, and Kolkata, India. Clin Vaccine Immunol 2014; 21:661-6; PMID:24599532; http://dx.doi.org/10.1128/CVI.00791-13
   PubMed Web of Science ®Google Scholar
• Thiem VD, Lin FY, Canh do G, Son NH, Anh DD, Mao ND, Chu C, Hunt SW, Robbins JB, Schneerson R, et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011; 18:730-5; PMID:21411598; http://dx.doi.org/10.1128/CVI.00532-10
   PubMed Web of Science ®Google Scholar
• Chinnasami B, Sadasivam K, Vivekanandhan A, Arunachalam P, Pasupathy S. A Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (Pedatyph™) in Children. J Clin Diagnostic Res 2015; 9:1-3; http://dx.doi.org/10.1111/crj.12091
   Web of Science ®Google Scholar
• Lanh MN, Lin F-YC, Bay PV, Cong TT, Ho VA, Bryla DA, Chu C-Y, Shiloach J, Robbins JB, Schneerson R, et al. Persistence of antibodies and efficacy against typhoid fever 28–46 months following Vi conjugate vaccine (Vi-rEPA) in 2 to 5 years-old children. N Engl J Med 2003; 349:1390-91; PMID:14523155; http://dx.doi.org/10.1056/NEJM200310023491423
   PubMed Web of Science ®Google Scholar
• Lin FY, Vo AH, Phan VB, Nguyen TT, Bryla D, Tran CT, Ha BK, Dang DT, Robbins JB. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg 2000; 62:644-8; PMID:11289678
   PubMed Web of Science ®Google Scholar
• Saha SK, Baqui AH, Hanif M, Darmstadt GL, Ruhulamin M, Nagatake T, Santosham M, Black RE. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J 2001; 20:521-4; PMID:11368111; http://dx.doi.org/10.1097/00006454-200105000-00010
   PubMed Web of Science ®Google Scholar
• Jones C. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An Acad Bras Cienc 2005; 77:293-324; PMID:15895165; http://dx.doi.org/10.1590/S0001-37652005000200009
   PubMed Web of Science ®Google Scholar
• Finn A. Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 2004; 70:1-14; PMID:15339854; http://dx.doi.org/10.1093/bmb/ldh021
   PubMed Web of Science ®Google Scholar
• Vliegenthart JF. Carbohydrate based vaccines. FEBS Lett 2006; 580:2945-50; PMID:16630616; http://dx.doi.org/10.1016/j.febslet.2006.03.053
   PubMed Web of Science ®Google Scholar
• Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, Hunt S, Schneerson R, Robbins JB, Chu C, et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 2004; 72:6586-8; PMID:15501790; http://dx.doi.org/10.1128/IAI.72.11.6586-6588.2004
   PubMed Web of Science ®Google Scholar
• Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, Bhutta ZA, Canh do G, Ali M, Shin S, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ 2008; 86:260-8; PMID:18438514; http://dx.doi.org/10.2471/BLT.06.039818
   PubMed Web of Science ®Google Scholar
• Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, Bryla DA, Chu C, Schiloach J, Robbins JB, Schneerson R, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Eng J Med 2003; 349:1390-1; PMID:14523155; http://dx.doi.org/10.1056/NEJM200310023491423
   PubMed Web of Science ®Google Scholar
• Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-9; PMID:11320385; http://dx.doi.org/10.1056/NEJM200104263441701
   PubMed Web of Science ®Google Scholar
• Szu SC, Lin KF, Hunt S, Chu C, Thinh ND. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine. Vaccine 2014; 32:2618-22; PMID:24657719; http://dx.doi.org/10.1016/j.vaccine.2014.03.023
   PubMed Web of Science ®Google Scholar
• Meeting of the Immunization Strategic Advisory Group of Experts, November 2007–conclusions and recommendations. Wkly Epidemiol Rec 2008; 83:1-15; PMID:18175408
   PubMedGoogle Scholar
• Sur D, Ali M, von Seidlein L, Manna B, Deen JL, Acosta CJ, Clemens JD, Bhattacharya SK. Comparisons of predictors for typhoid and paratyphoid fever in Kolkata, India. BMC Public Health 2007; 7:289; PMID:17935611; http://dx.doi.org/10.1186/1471-2458-7-289
   PubMed Web of Science ®Google Scholar
• Date KA, Bentsi-Enchill AD, Fox KK, Abeysinghe N, Mintz ED, Khan MI, Sahastrabuddhe S, Hyde TB, Centers for Disease C, Prevention. Typhoid Fever surveillance and vaccine use - South-East Asia and Western Pacific regions, 2009-2013. MMWR Morbidity Mortality Weekly Report 2014; 63:855-60; PMID:25275329
   PubMed Web of Science ®Google Scholar
• Indian Council of Medical Research. Ethical Guidelines for Biomedical Research on Human Participants. Accessed on May 29, 2015 Available at http://icmrnicin/ethical_guidelinespdf 2006
   Google Scholar
• Drugs and Cosmetics (IInd Amendment) Rules. Schedule Y. Accessed on May 29, 2015 Available at http://dbtbiosafetynicin/act/schedule_ypdf 2005
   Google Scholar
• Vitale G, Librizzi R, Mocciaro C, Friscia I, Blandino E, Usticano V, Mansueto S, Di Fiore M, Reina G, Gambino G. An ELISA method in the diagnosis of typhoid fever. J Clin Lab Immunol 1990; 31:195-9; PMID:1967064
   PubMedGoogle Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline guideline for good clinical practice E6. Accessed on May 28, 2015 Available at http://wwwichorg/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guidelinepdf 1996
   Google Scholar